Glucagon-Like Peptide 1 in the Brain: Where Is It Coming From, Where Is It Going?
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is likely best known by many readers of Diabetes because of the role it plays in insulin secretion. Indeed, GLP-1 receptor (GLP-1R) agonists have become important tools for glycemic control in the treatment of type 2 diabetes. In addition to its incretin effects, GLP-1 signaling plays a role in the control of feeding (1) and other motivated behaviors such as fluid intake (2) and drug taking (3,4). Although many of the effects of GLP-1 are known to be mediated at least in part by activation of central GLP-1Rs, the source(s) of endogenous GLP-1 that activate these receptors remain unclear. Complicating this issue is the fact that GLP-1 is produced both peripherally in the ileum, from which it is released into circulation, and centrally in limited regions of the brain that include the nucleus of the solitary tract (NTS) and the olfactory bulb (1,5) (Fig. 1). Figure 1 GLP-1 interactions with the brain. GLP-1–producing cells (yellow circles) are found in areas including the ileum, olfactory bulb, and hindbrain. GLP-1–responsive structures in the brain are far more distributed and include structures behind (blue) and outside of (red) the blood-brain barrier, a subset of which are represented in this schematic. Knowing which source of GLP-1 acts on which of the responsive structures is important in order to understand the …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 1×
“For example, GLP-1R activation in the arcuate nucleus of the hypothalamus is important for glycemic control but not feeding (12), whereas GLP-1R activation in areas including the ventral tegmental area of the mesolimbic reward system is important for energy balance control but does not induce the nausea/malaise that c…”
BackgroundInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · cited 1×
“Food and Drug Administration– approved GLP-1R agonists act in the body, it is critical to keep in mind that the long-acting GLP-1R agonists exendin4 and liraglutide can penetrate the central nervous system and access blood-brain barrier–protected sites to influence GLP-1–mediated responses such as food intake and body…”
BackgroundYamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294
Holt, M. K., Richards, J. E., Cook, D. R., Brierley, D. I., Williams, D. L., Reimann, F., Gribble, F. M., & Trapp, S. (2019) · Diabetes · doi:10.2337/db18-0729 · Cited by 212 · cited 5×
“(7) approach the question of GLP-1 origin in feeding behavior using a mouse model that expresses Cre-recombinase under the control of the glucagon promoter.”
BackgroundInfluentialSchmidt, H. D., Mietlicki-Baase, E. G., Ige, K. Y., Maurer, J. J., Reiner, D. J., Zimmer, D. J., Van Nest, D. S., Guercio, L. A., Wimmer, M. E., Olivos, D. R., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.362 · Cited by 148 · cited 1×
“In addition to its incretin effects, GLP-1 signaling plays a role in the control of feeding (1) and other motivated behaviors such as fluid intake (2) and drug taking (3,4).”
BackgroundSelf-citationMcKay, N. J., Kanoski, S. E., Hayes, M. R., & Daniels, D. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00472.2011 · Cited by 79 · cited 1×
“In addition to its incretin effects, GLP-1 signaling plays a role in the control of feeding (1) and other motivated behaviors such as fluid intake (2) and drug taking (3,4).”
BackgroundSelf-citationMcKay, N. J., Galante, D. L., & Daniels, D. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3267-14.2014 · Cited by 55 · cited 1×
“For instance, studies comparing GLP-1 and GLP-1 precursor gene expression after feeding or drinking found that feeding increased both plasma GLP-1 and preproglucagon (PPG) mRNA in the hindbrain, whereas drinking had no detectable effect on plasma GLP-1 but increased PPG mRNA in the hindbrain (6).”
BackgroundSelf-citation
Cited by
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
Kabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
Ribeiro-Silva, J. C., Tavares, C. A. M., & Girardi, A. C. C. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102355 · Cited by 71
Qin, W., Ying, W., Hamaker, B., & Zhang, G. (2021) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12808 · Cited by 48
Metadata
- Authors
- Daniels, D., & Mietlicki-Baase, E. G.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2018-12-13
- Volume
- 68
- Issue
- 1
- Pages
- 15-17
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2906464266
- Cited by
- 46
- References
- 9
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.